Cargando…
Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017
Antimicrobial agents used to treat infections are life-saving. Overuse may result in more frequent adverse effects and emergence of multidrug-resistant microorganisms. In 2016–17, we performed the second point-prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247463/ https://www.ncbi.nlm.nih.gov/pubmed/30458917 http://dx.doi.org/10.2807/1560-7917.ES.23.46.1800393 |
_version_ | 1783372478805966848 |
---|---|
author | Plachouras, Diamantis Kärki, Tommi Hansen, Sonja Hopkins, Susan Lyytikäinen, Outi Moro, Maria Luisa Reilly, Jacqui Zarb, Peter Zingg, Walter Kinross, Pete Weist, Klaus Monnet, Dominique L Suetens, Carl |
author_facet | Plachouras, Diamantis Kärki, Tommi Hansen, Sonja Hopkins, Susan Lyytikäinen, Outi Moro, Maria Luisa Reilly, Jacqui Zarb, Peter Zingg, Walter Kinross, Pete Weist, Klaus Monnet, Dominique L Suetens, Carl |
author_sort | Plachouras, Diamantis |
collection | PubMed |
description | Antimicrobial agents used to treat infections are life-saving. Overuse may result in more frequent adverse effects and emergence of multidrug-resistant microorganisms. In 2016–17, we performed the second point-prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European acute care hospitals. We included 1,209 hospitals and 310,755 patients in 28 of 31 European Union/European Economic Area (EU/EEA) countries. The weighted prevalence of antimicrobial use in the EU/EEA was 30.5% (95% CI: 29.2–31.9%). The most common indication for prescribing antimicrobials was treatment of a community-acquired infection, followed by treatment of HAI and surgical prophylaxis. Over half (54.2%) of antimicrobials for surgical prophylaxis were prescribed for more than 1 day. The most common infections treated by antimicrobials were respiratory tract infections and the most commonly prescribed antimicrobial agents were penicillins with beta-lactamase inhibitors. There was wide variation of patients on antimicrobials, in the selection of antimicrobial agents and in antimicrobial stewardship resources and activities across the participating countries. The results of the PPS provide detailed information on antimicrobial use in European acute care hospitals, enable comparisons between countries and hospitals, and highlight key areas for national and European action that will support efforts towards prudent use of antimicrobials. |
format | Online Article Text |
id | pubmed-6247463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | European Centre for Disease Prevention and Control (ECDC) |
record_format | MEDLINE/PubMed |
spelling | pubmed-62474632018-12-06 Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 Plachouras, Diamantis Kärki, Tommi Hansen, Sonja Hopkins, Susan Lyytikäinen, Outi Moro, Maria Luisa Reilly, Jacqui Zarb, Peter Zingg, Walter Kinross, Pete Weist, Klaus Monnet, Dominique L Suetens, Carl Euro Surveill Surveillance and Outbreak Report Antimicrobial agents used to treat infections are life-saving. Overuse may result in more frequent adverse effects and emergence of multidrug-resistant microorganisms. In 2016–17, we performed the second point-prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European acute care hospitals. We included 1,209 hospitals and 310,755 patients in 28 of 31 European Union/European Economic Area (EU/EEA) countries. The weighted prevalence of antimicrobial use in the EU/EEA was 30.5% (95% CI: 29.2–31.9%). The most common indication for prescribing antimicrobials was treatment of a community-acquired infection, followed by treatment of HAI and surgical prophylaxis. Over half (54.2%) of antimicrobials for surgical prophylaxis were prescribed for more than 1 day. The most common infections treated by antimicrobials were respiratory tract infections and the most commonly prescribed antimicrobial agents were penicillins with beta-lactamase inhibitors. There was wide variation of patients on antimicrobials, in the selection of antimicrobial agents and in antimicrobial stewardship resources and activities across the participating countries. The results of the PPS provide detailed information on antimicrobial use in European acute care hospitals, enable comparisons between countries and hospitals, and highlight key areas for national and European action that will support efforts towards prudent use of antimicrobials. European Centre for Disease Prevention and Control (ECDC) 2018-11-15 /pmc/articles/PMC6247463/ /pubmed/30458917 http://dx.doi.org/10.2807/1560-7917.ES.23.46.1800393 Text en This article is copyright of The Authors, 2018. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
spellingShingle | Surveillance and Outbreak Report Plachouras, Diamantis Kärki, Tommi Hansen, Sonja Hopkins, Susan Lyytikäinen, Outi Moro, Maria Luisa Reilly, Jacqui Zarb, Peter Zingg, Walter Kinross, Pete Weist, Klaus Monnet, Dominique L Suetens, Carl Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 |
title | Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 |
title_full | Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 |
title_fullStr | Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 |
title_full_unstemmed | Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 |
title_short | Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 |
title_sort | antimicrobial use in european acute care hospitals: results from the second point prevalence survey (pps) of healthcare-associated infections and antimicrobial use, 2016 to 2017 |
topic | Surveillance and Outbreak Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247463/ https://www.ncbi.nlm.nih.gov/pubmed/30458917 http://dx.doi.org/10.2807/1560-7917.ES.23.46.1800393 |
work_keys_str_mv | AT plachourasdiamantis antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT karkitommi antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT hansensonja antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT hopkinssusan antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT lyytikainenouti antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT moromarialuisa antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT reillyjacqui antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT zarbpeter antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT zinggwalter antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT kinrosspete antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT weistklaus antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT monnetdominiquel antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT suetenscarl antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 AT antimicrobialuseineuropeanacutecarehospitalsresultsfromthesecondpointprevalencesurveyppsofhealthcareassociatedinfectionsandantimicrobialuse2016to2017 |